Other scientific evidence - SAVIMS

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Insights into mRNA Vaccine Concerns from Dalgleish and Malhotra

Director | 01/04/2023 | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Dalgleish, A. (2023, April 1). Narrative crumbles as doctors thank Aseem Malhotra and Angus Dalgleish for explaining how the mRNA vaccines are injuring their patients. Daily Sceptic. https://dailysceptic.org/2023/04/01/narrative-crumbles-as-doctors-thank-aseem-malhotra-and-angus-dalgleish-for-explaining-how-the-mrna-vaccines-are-injuring-their-patients/ Summary: In his article, Dr Angus Dalgleish expresses deep concern regarding the ongoing rollout of COVID-19 booster vaccines in the UK, arguing that they lack scientific […]

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Comprehensive Overview of Early COVID-19 Treatment Protocols

Director | 30/03/2023 | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Reference: FLCCC Alliance. (2023). I-CARE early COVID treatment summary. Retrieved from https://www.flccc.net Summary: The FLCCC Alliance outlines a structured protocol for the early treatment of COVID-19, emphasising the importance of immediate intervention after the onset of symptoms. First-line treatments include Ivermectin (0.4-0.6 mg/kg), Hydroxychloroquine (200 mg twice daily), and antiseptic mouthwash for symptom management. Ivermectin

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

I-CARE Early COVID Treatment Protocol Overview

Director | 30/03/2023 | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Reference: FLCCC Alliance. (2023). I-CARE: Early COVID treatment protocol. Retrieved from [insert link] Summary: The I-CARE protocol, developed by the FLCCC Alliance, aims to provide healthcare professionals with a structured approach to early COVID-19 treatment, focusing on preventing hospitalisation and mortality. The protocol recommends a combination of first-line treatments such as ivermectin, hydroxychloroquine, and various

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Alarming COVID-19 Death Statistics: The Vaccinated Majority

Director | 26/03/2023 | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: By The Exposé. (2023, March 26). UK Government quietly confirms Triple+ vaccinated accounted for 92% of COVID deaths in 2022. The Exposé. https://expose-news.com/2023/03/26/uk-gov-confirms-vaccinated-accounted-for-92-percent-of-covid-deaths-in-2022 Summary: An article by The Exposé highlights concerning statistics from the UK Government, revealing that the triple-vaccinated population accounted for 92% of COVID-19 deaths in 2022, raising questions about vaccine efficacy.

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Government Data Reveals Alarming COVID-19 Vaccine Death Rates

Director | 21/03/2023 | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: The Exposé. (2023, March 21). Government publishes shocking figures on COVID vaccine deaths: 1 in every 73 vaccinated people died by June 2022 compared to just 1 in every 172 not-vaccinated people. expose-news.com/2023/03/21/1-in-73-covid-vaccinated-died-by-june-22 Summary: According to data from the UK Office for National Statistics (ONS), by June 2022, 1 in every 73 vaccinated individuals

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Confronting the COVID Vaccine Debate: A Call for Transparency

Director | 01/03/2023 | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Kirsch, S. (2023, March 1). Why is everyone so afraid to talk about the elephant in the room? Steve Kirsch. Substack. https://stevekirsch.substack.com/p/why-is-everyone-so-afraid-to-talk Summary: In his article, Steve Kirsch presents a critical view of the COVID-19 response, arguing that significant errors were made regarding vaccines, masks, social distancing, and lockdowns. He contends that vaccines have

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Effectiveness of the COVID-19 Bivalent Vaccine

Director | 23/02/2023 | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Shrestha, N. K., Burke, P. C., Nowacki, A. S., Simon, J. F., Hagen, A., & Gordon, S. M. (2022). Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine. medRxiv. https://doi.org/10.1101/2022.12.17.22283625 Summary: This study evaluated the effectiveness of the bivalent COVID-19 vaccine among 51,011 employees at the Cleveland Clinic. The results indicated a 30% effectiveness

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Comprehensive Prevention Strategies Against COVID-19, Influenza, and RSV – SUMMARY

Director | 02/02/2023 | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Reference: FLCCC Alliance. (2023). I-PREVENT COVID, FLU AND RSV protection. Retrieved from www.flccc.net Summary: The I-PREVENT protocol is designed for healthcare workers, high-risk individuals, and those with co-morbidities to mitigate the risks of COVID-19, influenza, and RSV infections. Recommended interventions include antiseptic mouthwashes containing chlorhexidine, povidone-iodine, or cetylpyridinium chloride, and supplementation with Vitamin D, Vitamin

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

Preventative Protocols for COVID-19, Influenza, and RSV

Director | 01/02/2023 | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

Reference: I-PREVENT. (2023). COVID, Flu and RSV protection. Retrieved from [source link if applicable, otherwise remove this line] Summary: The I-PREVENT protocol offers strategies for the prevention of COVID-19, influenza, and RSV. It includes pre-exposure and post-exposure prevention measures, particularly aimed at high-risk groups and healthcare workers. The pre-exposure approach recommends the use of antiseptic

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Association of Guillain-Barré Syndrome with COVID-19 Vaccination

Director | 01/02/2023 | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Abara, W. E., Gee, J., Marquez, P., Woo, J., Myers, T. R., DeSantis, A., Baumblatt, J. A. G., Woo, E. J., Thompson, D., Nair, N., Su, J. R., Shimabukuro, T. T., & Shay, D. K. (2023). Reports of Guillain-Barré syndrome after COVID-19 vaccination in the United States. JAMA Network Open, 6(2), e2253845. https://doi.org/10.1001/jamanetworkopen.2022.53845 Summary: